Healthcare Sales & Marketing Network News: pulmonary hypertension

Searching News Database: pulmonary hypertension

HSMN NewsFeed - 2 Jan 2024
Pulnovo Medical Announces PADN Receives FDA HUD Designation and US CMS Medicare Coverage Code and NMPA Approval
Devices Regulatory FDA Reimbursement

HSMN NewsFeed - 9 Oct 2023
Endotronix Receives IDE Approval for the Market Expanding PROACTIVE-HF 2 Clinical Trial
Devices Interventional Cardiology FDA

HSMN NewsFeed - 9 Jan 2023
SoniVie Raises $60m in Round C Financing, and Appoints New Board Members
Devices Venture Capital

HSMN NewsFeed - 9 Dec 2022
Janssen Submits Biologics License Application to U.S. FDA for Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 13 Jul 2022
SoniVie Announces successful procedure with TIVUS system on first patient enrolled for REDUCED1 Pilot study
Devices

HSMN NewsFeed - 21 Feb 2022
Abbott's CardioMEMS(TM) HF System Receives FDA Approval to Support Patients Battling Earlier-Stage Heart Failure
Devices Monitoring Cardiology FDA

HSMN NewsFeed - 15 Feb 2022
Cardiosense Receives FDA Breakthrough Device Designation for Algorithm to Identify Patients at Risk of Decompensated Heart Failure
Devices Cardiology FDA

HSMN NewsFeed - 8 Feb 2022
atHeart Medical Receives FDA Approval for the Second Phase of the ASCENT ASD U.S. IDE Trial
Devices Interventional Cardiology FDA

HSMN NewsFeed - 3 Feb 2022
Third Pole Therapeutics Closes $25M Financing - eNOfit(TM) Wearable Device Now Ready for Clinical Trials
Devices Venture Capital

HSMN NewsFeed - 8 Sep 2021
atHeart Medical Appoints Seasoned Medtech Executive Andrew Cleeland to Board of Directors
Devices Cardiology Personnel

HSMN NewsFeed - 14 Jul 2021
First Five Patients Successfully Treated with atHeart Medical's Novel reSept(TM) Atrial Septal Defect Occluder in U.S. IDE Pivotal Trial
Devices Interventional Cardiology

HSMN NewsFeed - 12 Jul 2021
Janssen Announces U.S. FDA Approval of DARZALEX FASPRO(R) (daratumumab and hyaluronidase-fihj) in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 23 Jun 2021
Veralox Therapeutics Appoints Michael Hanna As Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 1 Jun 2021
Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 20 Apr 2021
Newly Formed Company, atHeart Medical, Aims to Evolve Septal Closure with the reSept(TM) ASD Occluder
Devices Interventional Cardiology

HSMN NewsFeed - 1 Apr 2021
United Therapeutics Announces FDA Approval and Launch of Tyvaso(R) for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
Biopharmaceuticals FDA Product Launch

HSMN NewsFeed - 12 Mar 2021
Johnson & Johnson Single-Shot COVID-19 Vaccine Granted Emergency Use Listing by the World Health Organization
Biopharmaceuticals Regulatory

HSMN NewsFeed - 19 Feb 2021
Johnson & Johnson Announces Submission to World Health Organization for Emergency Use Listing of Investigational Single-Shot Janssen COVID-19 Vaccine Candidate
Biopharmaceuticals

HSMN NewsFeed - 4 Feb 2021
Johnson & Johnson Announces Submission of Application to the U.S. FDA for Emergency Use Authorization of its Investigational Single-Shot Janssen COVID-19 Vaccine Candidate
Biopharmaceuticals FDA

HSMN NewsFeed - 2 Feb 2021
Actimed Therapeutics Appoints Frank Misselwitz MD, PhD as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 2 Dec 2020
V-Wave Announces Appointment of Bill Hughes as Chief Financial Officer
Devices Interventional Cardiology Personnel

HSMN NewsFeed - 8 Oct 2020
Johnson & Johnson Announces European Commission Approval of Agreement to Supply 200 Million Doses of Janssen's COVID-19 Vaccine Candidate
Biopharmaceuticals

HSMN NewsFeed - 23 Sep 2020
Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen's COVID-19 Vaccine Candidate
Biopharmaceuticals

HSMN NewsFeed - 21 Sep 2020
Relief and NeuroRx Announce Partnership for Global Commercialization of RLF-100(TM) and Selection of Commercial Partners
Biopharmaceuticals

HSMN NewsFeed - 19 Aug 2020
Johnson & Johnson to Acquire Momenta Pharmaceuticals, Inc., Expanding Janssen's Leadership in Novel Treatments for Autoimmune Diseases
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 6 Aug 2020
FDA grants inhaled use IND for RLF-100 (aviptadil) to treat patients with moderate and severe COVID-19 aiming to prevent progression to respiratory failure
Biopharmaceuticals Drug Delivery FDA

HSMN NewsFeed - 5 Aug 2020
Johnson & Johnson Announces Agreement with U.S. Government for 100 Million Doses of Investigational COVID-19 Vaccine
Biopharmaceuticals

HSMN NewsFeed - 30 Jul 2020
Single Dose of Johnson & Johnson COVID-19 Vaccine Candidate Demonstrates Robust Protection in Pre-clinical Studies
Biopharmaceuticals

HSMN NewsFeed - 17 Jul 2020
Interim Six-Month Data of RPGR Gene Therapy Shows Significant Vision Improvement in Patients Living with X-Linked Retinitis Pigmentosa
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 14 Jul 2020
TREMFYA(R) (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis
Biopharmaceuticals FDA

HSMN NewsFeed - 26 Jun 2020
Janssen Announces Discontinuation of Phase 3 LOTUS Study Evaluating Ustekinumab in Systemic Lupus Erythematosus
Biopharmaceuticals

HSMN NewsFeed - 8 Apr 2020
Third Pole Therapeutics Announces Global Commercialization Agreement with Chiesi Group for Its Tankless, Portable Inhaled Nitric Oxide (iNO) Delivery System
Biopharmaceuticals Licensing

HSMN NewsFeed - 30 Mar 2020
Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19; Landmark New Partnership with U.S. Department of Health & Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use
Biopharmaceuticals

HSMN NewsFeed - 26 Mar 2020
FDA Grants VERO Biotech Expanded Access Emergency Use for the Treatment of Patients with COVID-19, with the GENOSYL(R) DS, the First and Only FDA-Approved Tankless System for the Delivery of Inhaled Nitric Oxide
Biopharmaceuticals Drug Delivery FDA

HSMN NewsFeed - 12 Mar 2020
Mallinckrodt Evaluates the Potential Role for Inhaled Nitric Oxide to Treat COVID-19 Associated Lung Complications, Engages with Scientific, Governmental and Regulatory Agencies
Biopharmaceuticals

HSMN NewsFeed - 8 Nov 2019
Janssen Announces Submission of Supplemental New Drug Application to U.S. FDA Seeking Approval of IMBRUVICA(R) (ibrutinib) in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 4 Oct 2019
Johnson & Johnson Commits $500 Million Investment Over Four Years to Help End the Epidemics of HIV and Tuberculosis
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 14 Jun 2019
Janssen reports top-line Phase 3 results for TREMFYA(R) (guselkumab) in adults with active psoriatic arthritis
Biopharmaceuticals

HSMN NewsFeed - 4 Jun 2019
GORE(R) CARDIOFORM ASD Occluder Receives FDA Approval for the Treatment of Atrial Septal Defects
Devices Interventional Cardiology FDA

HSMN NewsFeed - 6 May 2019
Mallinckrodt Announces Encouraging Interim Analysis Results in Phase 4 Registry of INOmax(R) (Nitric Oxide) Gas for Inhalation for Pulmonary Hypertension in Neonates
Biopharmaceuticals

HSMN NewsFeed - 1 Oct 2018
FDA Approves KYPROLIS(R) (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone (Kd70) For Patients With Relapsed Or Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 4 Sep 2018
United Therapeutics And MannKind Announce Collaboration For Pulmonary Hypertension Products
Biopharmaceuticals Licensing

HSMN NewsFeed - 30 Apr 2018
Actelion Submits Supplemental New Drug Application to US FDA Seeking Approval of OPSUMIT(R) (macitentan) for the Treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Biopharmaceuticals FDA

HSMN NewsFeed - 6 Sep 2017
Actelion Receives FDA Approval Of TRACLEER(R) (bosentan) For Use In Pediatric Patients With Pulmonary Arterial Hypertension
Biopharmaceuticals FDA

HSMN NewsFeed - 5 Jun 2017
Novoteris, LLC Receives FDA and Health Canada Clearance to Start a Phase 2 Clinical Trial of Its Thiolanox(R) Nitric Oxide for the Treatment of Cystic Fibrosis
Biopharmaceuticals Drug Delivery FDA

HSMN NewsFeed - 12 Apr 2017
Respira Therapeutics Announces Collaboration with United Therapeutics to Treat Pulmonary Hypertension
Biopharmaceuticals Devices Drug Delivery

HSMN NewsFeed - 23 Sep 2016
Validity of Mallinckrodt's INOMAX(R) Patent Claims Upheld
Biopharmaceuticals Devices Litigation

HSMN NewsFeed - 20 Sep 2016
KVK Tech Announces FDA-Approval of Lomaira(TM) (phentermine hydrochloride USP) 8 mg tablets, CIV, A Low-Cost, Low-Dose Phentermine That Can Be Used Up To Three Times Daily for Weight Reduction
Biopharmaceuticals FDA

HSMN NewsFeed - 4 Jul 2016
European Commission Approves Extended Indication For Amgen's Kyprolis(R) (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma Patients
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 30 Oct 2015
Mallinckrodt's INOmax(R) Approved In Australia And Japan For Pulmonary Hypertension In Conjunction With Heart Surgery
Biopharmaceuticals Regulatory

HSMN NewsFeed - 15 Sep 2015
Bellerophon Therapeutics Announces Leadership Team Changes
Devices Drug Delivery Personnel

HSMN NewsFeed - 15 Sep 2015
Harpoon Medical Enrolls Ten Patients in Early Feasibility Study with 100% Procedural Success
Devices Surgery Cardiology

HSMN NewsFeed - 6 Nov 2014
HD Medical Offers Viscope Md World’s First Visual Stethoscope with Murmur Detection at MEDICA
Devices Cardiology Product Launch

HSMN NewsFeed - 27 Oct 2014
Zogenix Acquires U.K.-Based Brabant Pharma
Biopharmaceuticals Neurology Mergers & Acquisitions

HSMN NewsFeed - 23 May 2014
EkoSonic(R) Endovascular System Receives FDA Clearance for the Treatment of Pulmonary Embolism in the USA
Devices Interventional FDA

HSMN NewsFeed - 10 Feb 2014
Mast Therapeutics Signs Definitive Agreement To Acquire Aires Pharmaceuticals, Inc.
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 20 Jan 2014
Pulmonary Embolism Trial Comparing Endovascular Ultrasound to Standard of Care Anticoagulation Published in the American Heart Association’s Journal, Circulation
Devices Interventional

HSMN NewsFeed - 6 Jan 2014
Soligenix Appoints Richard Straube, MD, as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 23 Sep 2013
Bayer receives approval for Adempas(R) as first drug to treat rare heart and lung disease
Biopharmaceuticals Regulatory

HSMN NewsFeed - 17 Apr 2013
VentriPoint Receives CE Mark for Major Expansion of Its VMST Platform for Right Heart Analysis
Devices Cardiology Regulatory

HSMN NewsFeed - 11 Feb 2013
Bayer Submits New Drug Application for Riociguat for the Treatment of Pulmonary Arterial Hypertension and Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension
Biopharmaceuticals

HSMN NewsFeed - 22 Oct 2012
Bayer's Investigational Riociguat Meets Primary Endpoint in Phase III Study in Patients with Pulmonary Arterial Hypertension (PAH)
Biopharmaceuticals

HSMN NewsFeed - 20 Sep 2012
Seattle Children's Hospital Acquires VentriPoint Heart Analysis System
Diagnostics Cardiology

HSMN NewsFeed - 5 Sep 2012
Third Critically Ill Patient Successfully Treated With Pluristem's PLX Cells Under Compassionate Use
Regenerative Medicine Oncology

HSMN NewsFeed - 6 Aug 2012
Life of Cancer Patient Suffering From Bone Marrow Failure Saved Following Treatment With Pluristem's PLX Cells
Regenerative Medicine Oncology

HSMN NewsFeed - 20 Jul 2012
Onyx Pharmaceuticals Receives FDA Accelerated Approval of Kyprolis(TM) (carfilzomib) for Injection
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 29 Jun 2012
Actelion Pharmaceuticals Announces U.S. Food and Drug Administration Approval of Supplemental New Drug Application for Second Generation VELETRI(R) (epoprostenol) for Injection
Biopharmaceuticals FDA

HSMN NewsFeed - 16 Sep 2011
Natus Acquires Embla Systems LLC - Leading Sleep Diagnostic Company
Devices Mergers & Acquisitions

HSMN NewsFeed - 5 May 2011
The European Commission Approves Pfizer’s Revatio(R) (sildenafil) for the Treatment of Pulmonary Arterial Hypertension in Children
Biopharmaceuticals Regulatory

HSMN NewsFeed - 21 Jan 2011
Lantheus Medical Imaging Announces New National Contract with Novation for ABLAVAR(R) and DEFINITY(R)
Biopharmaceuticals Radiology Distribution

HSMN NewsFeed - 17 Jan 2011
EKOS Corporation Receives CE Mark to Treat Massive and Sub-Massive Pulmonary Embolism
Devices Regulatory

HSMN NewsFeed - 5 Jan 2011
FDA Extends Marketing Exclusivity for INOMAX(R)
Biopharmaceuticals FDA

HSMN NewsFeed - 1 Sep 2010
Pfizer to Acquire FoldRx Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 25 Aug 2010
Actelion Pharmaceuticals Announces FDA Approval of Brand Name for Commercially Available VELETRI(R) (epoprostenol for injection) for Pulmonary Arterial Hypertension
Biopharmaceuticals FDA

HSMN NewsFeed - 15 Jul 2010
Ikaria(R) Names Chief Science Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 14 Jun 2010
Instituto Nacional de Cardiologia First Center in Mexico to Treat Atrial Septal Defect with GORE(R) HELEX Septal Occluder
Devices Interventional Cardiology

HSMN NewsFeed - 1 Jun 2010
Ikaria(R) Names New Head of Research & Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 22 Apr 2010
Actelion Pharmaceuticals Announces Commercial Availability of Epoprostenol for Injection for the Treatment of Pulmonary Arterial Hypertension
Biopharmaceuticals

HSMN NewsFeed - 9 Mar 2010
FDA Clears GeNO LLC Investigational New Drug Application for Nitric Oxide Delivery System
Devices Drug Delivery

HSMN NewsFeed - 5 Oct 2009
FDA Advisory Committee Recommends Approval of PEGINTRON(R) for the Adjuvant Treatment of Stage III Malignant Melanoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 26 May 2009
FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension
Biopharmaceuticals FDA

HSMN NewsFeed - 9 Apr 2009
NMT Medical Receives PMA Approval for STARFlex as a Ventricular Septal Defect Repair Implant
Devices Interventional Cardiology FDA

HSMN NewsFeed - 7 Apr 2009
EPIX Pharmaceuticals Announces Sale of U.S., Canadian and Australian Rights for MS-325 (formerly marketed as Vasovist, gadofosveset trisodium, by Bayer Schering Pharma) to Lantheus Medical Imaging, Inc.
Biopharmaceuticals Radiology Acquisitions

HSMN NewsFeed - 28 Oct 2008
Gilead Announces Two-Year Clinical Data for Letairis(R) (ambrisentan) for the Treatment of Pulmonary Arterial Hypertension (WHO Group 1)
Biopharmaceuticals

HSMN NewsFeed - 23 Oct 2008
EPIX Pharmaceuticals Announces Reduction in Force
Biopharmaceuticals

HSMN NewsFeed - 1 Jul 2008
Ikaria(R) Strengthens Research & Development Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 20 Jun 2008
Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease
Biopharmaceuticals

HSMN NewsFeed - 29 May 2008
Gilead and Navitas Announce Agreement for Cicletanine for the Treatment of Pulmonary Arterial Hypertension
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 29 May 2008
Data from Pivotal Phase III Studies of Gilead's Letairis(R) (ambrisentan) for Pulmonary Arterial Hypertension (WHO Group 1) in Patients with WHO Functional Class II or III Symptoms Published in Circulation
Biopharmaceuticals

HSMN NewsFeed - 30 Apr 2008
Aradigm Announces Data Showing No Occurrence of Primary Lung Cancer in Patients Treated with AERx(R) Insulin Diabetes Management System (iDMS)
Biopharmaceuticals Drug Delivery Endocrinology

HSMN NewsFeed - 28 Apr 2008
Teva Announces Approval of Generic Flolan(R) for Injection
Biopharmaceuticals Generics FDA

HSMN NewsFeed - 31 Jan 2008
Encysive Pharmaceuticals Launches THELIN (Sitaxentan Sodium) in Sweden
Biopharmaceuticals

HSMN NewsFeed - 14 Jan 2008
Encysive Pharmaceuticals Launches THELIN (sitaxentan sodium) in Belgium and Luxembourg
Biopharmaceuticals

HSMN NewsFeed - 18 Dec 2007
Anthera's A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
Biopharmaceuticals FDA

HSMN NewsFeed - 11 Dec 2007
PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity
Biopharmaceuticals

HSMN NewsFeed - 10 Dec 2007
Long-Term Soliris(R) Therapy Improved or Stabilized Kidney Function in Patients With PNH
Biopharmaceuticals

HSMN NewsFeed - 4 Dec 2007
Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients
Biopharmaceuticals

HSMN NewsFeed - 26 Nov 2007
Encysive Pharmaceuticals Launches Thelin (sitaxentan sodium) in Italy
Biopharmaceuticals

HSMN NewsFeed - 8 Nov 2007
FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
Biopharmaceuticals FDA Oncology

HSMN NewsFeed - 29 Oct 2007
Gilead Announces 48-Week Data Evaluating Switching from Combivir(R) To Truvada(R) Among Virologically-Suppressed HIV Patients
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 25 Oct 2007
Aradigm Corporation Reports Initial Human Data on a Novel Approach to Treatment of Tobacco Smoking Addiction Using its AERx Essence(R) Nicotine Inhaler
Devices Drug Delivery

HSMN NewsFeed - 24 Oct 2007
Encysive Pharmaceuticals Announces Long-Term Study of Sitaxsentan Presented At Chest Meeting
Biopharmaceuticals

HSMN NewsFeed - 23 Oct 2007
Gilead Announces New LetairisTM (ambrisentan) Data for the Treatment of Patients with Pulmonary Arterial Hypertension (WHO Group 1)
Biopharmaceuticals

HSMN NewsFeed - 4 Oct 2007
Acorn Acquisition Corp Announces Definitive Agreement to Acquire Lumen Medical Inc.
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 3 Oct 2007
FDA Approves GORE HELEX Septal Occluder for Treatment of Atrial Septal Defect
Devices FDA Interventional Cardiology

HSMN NewsFeed - 1 Oct 2007
Ikaria Names Executive Vice President of Research and Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 13 Sep 2007
Encysive Pharmaceuticals Announces Launch of THELIN (sitaxentan sodium) in Spain
Biopharmaceuticals

HSMN NewsFeed - 10 Sep 2007
AGA Medical Corporation Receives Approval for the AMPLATZER Muscular Ventricular Septal Defect Occluder
Devices FDA Interventional Cardiology

HSMN NewsFeed - 6 Sep 2007
Aradigm and CyDex Sign Development Collaboration Agreement
Biopharmaceuticals Drug Delivery

HSMN NewsFeed - 20 Aug 2007
PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
Biopharmaceuticals

HSMN NewsFeed - 13 Jul 2007
Encysive Pharmaceuticals Provides Update for Thelin (Sitaxsentan Sodium)
Biopharmaceuticals

HSMN NewsFeed - 5 Jul 2007
Aradigm Corporation Names Norman Halleen as Interim Chief Financial Officer
Biopharmaceuticals Drug Delivery Personnel

HSMN NewsFeed - 22 Jun 2007
Alexion's Soliris(TM) Granted Marketing Approval in Europe for Treatment of All Patients With PNH
Biopharmaceuticals Regulatory

HSMN NewsFeed - 15 Jun 2007
U.S. Food and Drug Administration Approves Gilead's Letairis(TM) (ambrisentan) 5 mg and 10 mg Tablets for the Once-Daily Treatment of Pulmonary Arterial Hypertension (WHO Group 1) in Patients with WHO Functional Class II or III Symptoms
Biopharmaceuticals FDA

HSMN NewsFeed - 11 Jun 2007
Studies Show Efficacy and Safety of Alexion's Soliris(TM) in Broad Population of PNH Patients
Biopharmaceuticals

HSMN NewsFeed - 5 Jun 2007
Aradigm Names D. Jeffery Grimes as General Counsel and Corporate Secretary
Biopharmaceuticals Drug Delivery Personnel

HSMN NewsFeed - 4 Jun 2007
Soliris(TM) Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes
Biopharmaceuticals Oncology

HSMN NewsFeed - 30 May 2007
Canadian Health Authority Approves THELIN (Sitaxsentan Sodium) for Pulmonary Arterial Hypertension
Biopharmaceuticals Regulatory

HSMN NewsFeed - 21 May 2007
Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
Biopharmaceuticals

HSMN NewsFeed - 27 Apr 2007
CHMP Adopts Positive Opinion for Alexion's Soliris(TM) in Europe
Biopharmaceuticals Regulatory

HSMN NewsFeed - 23 Apr 2007
Hemispherx and Armada Health Care enter Agreement to Launch Alferon N Injection(R) via Specialty Pharmacy Network
Biopharmaceuticals

HSMN NewsFeed - 16 Apr 2007
Encysive Pharmaceuticals Announces Launch of THELIN (Sitaxentan Sodium) in the Netherlands
Biopharmaceuticals Regulatory

HSMN NewsFeed - 2 Apr 2007
EPIX Provides Update Regarding Status of Vasovist(TM) Appeal
Biopharmaceuticals Radiology FDA

HSMN NewsFeed - 2 Apr 2007
Encysive Pharmaceuticals Announces Launch of Thelin (Sitaxentan Sodium) in Republic of Ireland
Biopharmaceuticals

HSMN NewsFeed - 29 Mar 2007
Proteo, Inc./Proteo Biotech AG: European Commission grants Orphan Drug Status to Elafin for the treatment of PAH
Biopharmaceuticals Regulatory

HSMN NewsFeed - 26 Mar 2007
Bosentan -- Tracleer -- Receives Positive EU Opinion for Reduction of New Digital Ulcerations in Systemic Sclerosis Patients
Biopharmaceuticals

HSMN NewsFeed - 19 Mar 2007
Update: FDA Approves Alexion's Soliris(TM) for All Patients With PNH
Biopharmaceuticals FDA

HSMN NewsFeed - 16 Mar 2007
FDA Approves Alexion's Soliris(TM) for All Patients With PNH
Biopharmaceuticals FDA

HSMN NewsFeed - 5 Mar 2007
Actelion: Positive Study With Bosentan (Tracleer) in CTEPH
Biopharmaceuticals

HSMN NewsFeed - 28 Feb 2007
Vascular BioSciences Extends Patent Portfolio
Biopharmaceuticals

HSMN NewsFeed - 28 Feb 2007
EPIX Pharmaceuticals Files Formal Appeal for Vasovist(TM) with the Center for Drug Evaluation and Research
Biopharmaceuticals FDA

HSMN NewsFeed - 26 Feb 2007
United Therapeutics Announces Pulmonary Hypertension Opinion Leaders' Guidance On Intravenous Therapies
Biopharmaceuticals

HSMN NewsFeed - 8 Feb 2007
Results of Inhaled Treprostinil Controlled Pilot Studies Reported in the Journal of the American College Of Cardiology
Biopharmaceuticals Cardiology

HSMN NewsFeed - 5 Feb 2007
EPIX Pharmaceuticals Presents Data from Novel MRI Imaging Agent at the Society for Cardiovascular Magnetic Resonance Meeting
Biopharmaceuticals Radiology Cardiology

HSMN NewsFeed - 2 Feb 2007
Veteran Pharmaceutical Executive Joins AerovectRx Corp. Board
Biopharmaceuticals Personnel

HSMN NewsFeed - 16 Jan 2007
Aradigm Receives FDA Orphan Drug Designation for Liposomal Ciprofloxacin for Bronchiectasis
Biopharmaceuticals FDA

HSMN NewsFeed - 18 Dec 2006
Successful Study With Tracleer(r) in Patients With Mildly Symptomatic Pulmonary Arterial Hypertension
Biopharmaceuticals

HSMN NewsFeed - 14 Dec 2006
EPIX Pharmaceuticals to File Appeal with the Center for Drug Evaluation and Research for Vasovist(TM)
Biopharmaceuticals FDA

HSMN NewsFeed - 12 Dec 2006
United Therapeutics Affiliate Initiates First-Ever Gene-Therapy Trial for Pulmonary Arterial Hypertension
Biopharmaceuticals Regenerative Medicine

HSMN NewsFeed - 12 Dec 2006
Northern Therapeutics and MaxCyte Initiate Landmark Engineered Cell Therapy Trial for Fatal Lung Disease
Biopharmaceuticals Regenerative Medicine

HSMN NewsFeed - 11 Dec 2006
Actelion-1 -- First Tissue-Targeting Endothelin Receptor Antagonist -- in Phase III for Pulmonary Hypertension
Biopharmaceuticals

HSMN NewsFeed - 20 Nov 2006
Actelion Announces Definitive Agreement to Acquire U.S.-Based CoTherix, Inc.
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 14 Nov 2006
FDA Grants Priority Review for Soliris(TM) (eculizumab) BLA for Treatment of Paroxysmal Nocturnal Hemoglobinuria
Biopharmaceuticals FDA

HSMN NewsFeed - 6 Nov 2006
EPIX Announces Canadian Approval of Vasovist(TM); Marks 30th Country in Which Vasovist is Approved for Marketing
Biopharmaceuticals Regulatory Radiology

HSMN NewsFeed - 2 Oct 2006
Gilead Sciences to Acquire Myogen, Inc. for $2.5 Billion
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 26 Sep 2006
Alexion Submits Market Authorization Application for Soliris(TM) (eculizumab) in the Treatment of Paroxysmal Nocturnal Hemoglobinuria to the European Medicines Agency
Biopharmaceuticals Regulatory

HSMN NewsFeed - 21 Sep 2006
EPIX Pharmaceuticals Announces Top-line Results from Phase 3 Trial of PRX-00023 in Generalized Anxiety Disorder
Biopharmaceuticals

HSMN NewsFeed - 20 Sep 2006
EPIX Announces Australian Approval of Vasovist(TM)
Biopharmaceuticals Regulatory

HSMN NewsFeed - 7 Sep 2006
Myogen Initiates Open-Label Phase 3 Clinical Trial of Ambrisentan in Patients with Pulmonary Hypertension
Biopharmaceuticals

HSMN NewsFeed - 13 Jul 2006
EPIX Pharmaceuticals Retains Full Rights to Fibrin-Binding Imaging Agent EP-2104R as Schering AG Decides Not to Exercise Option for Development Program
Biopharmaceuticals Radiology

HSMN NewsFeed - 30 Jun 2006
EPIX Pharmaceuticals Files Appeal with FDA Regarding Vasovist(TM) Approvable Letters
Biopharmaceuticals Radiology FDA

HSMN NewsFeed - 28 Jun 2006
CoTherix Licenses Exclusive Rights to Develop and Commercialize Oral and Inhaled Formulations of Fasudil for the Treatment of PAH and Stable Angina in North America and Europe From Asahi Kasei Pharma
Biopharmaceuticals Licensing

HSMN NewsFeed - 2 Jun 2006
Encysive Pharmaceuticals' Thelin(TM) (sitaxentan sodium) Receives Positive Opinion From European Authorities
Biopharmaceuticals Regulatory

HSMN NewsFeed - 24 May 2006
Predix Pharmaceuticals Achieves Full Enrollment for Phase III Clinical Trial of PRX-00023 in Generalized Anxiety Disorder
Biopharmaceuticals

Return to NewsFeed

Additional items found! 50

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 50 additional stories matching:
pulmonary hypertension
(Password required)

FindReps - available on the Apple App Store for iPhone and iPad.